SILEXION THERAPEUTICS CORP Increase (Decrease) in Accrued Liabilities
SILEXION THERAPEUTICS CORP (SLXN) reported Increase (Decrease) in Accrued Liabilities of $102.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-03-17
- SILEXION THERAPEUTICS CORP increase (decrease) in accrued liabilities for the quarter ending 2025-03-31 was -$90.00K.
- SILEXION THERAPEUTICS CORP increase (decrease) in accrued liabilities for the quarter ending 2024-12-31 was -$1.01M, a 299.41% decline year-over-year.
- SILEXION THERAPEUTICS CORP increase (decrease) in accrued liabilities for the quarter ending 2024-09-30 was -$905.00K, a 2842.42% decline year-over-year.
- SILEXION THERAPEUTICS CORP increase (decrease) in accrued liabilities for the quarter ending 2024-06-30 was $327.00K.
- SILEXION THERAPEUTICS CORP increase (decrease) in accrued liabilities for fiscal 2025 was $102.00K.
- SILEXION THERAPEUTICS CORP increase (decrease) in accrued liabilities for fiscal 2024 was -$1.90M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $102.00K 10-K · filed 2026-03-17 | |||
| 2025-03-31 | -$90.00K 10-Q · filed 2025-05-13 | -$1.10M derived: sum of 2 quarters · filed 2026-03-17 | -$2.01M derived: sum of 3 quarters · filed 2026-03-17 | -$1.68M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$1.92M derived: sum of 2 quarters · filed 2026-03-17 | -$1.59M derived: sum of 3 quarters · filed 2026-03-17 | -$1.90M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$905.00K 10-Q · filed 2024-11-14 | -$578.00K derived: sum of 2 quarters · filed 2024-11-14 | -$884.00K 10-Q · filed 2024-11-14 | -$375.00K derived: sum of 4 quarters · filed 2025-08-20 |
| 2024-06-30 | $327.00K 10-Q · filed 2024-08-29 | $21.00K 10-Q · filed 2024-08-29 | $530.00K derived: sum of 3 quarters · filed 2025-08-20 | $563.00K derived: sum of 4 quarters · filed 2025-08-20 |
| 2024-03-31 | -$306.00K 10-Q · filed 2025-05-13 | $203.00K derived: sum of 2 quarters · filed 2025-08-20 | $236.00K derived: sum of 3 quarters · filed 2025-08-20 | $201.00K derived: sum of 4 quarters · filed 2025-08-20 |
| 2023-12-31 | $509.00K derived: 8-K 12 month − 10-Q 9 month · filed 2025-08-20 | $542.00K derived: sum of 2 quarters · filed 2025-08-20 | $507.00K derived: sum of 3 quarters · filed 2025-08-20 | $359.00K 8-K · filed 2025-08-20 |
| 2023-09-30 | $33.00K 10-Q · filed 2024-11-14 | -$2.00K derived: sum of 2 quarters · filed 2024-11-14 | -$150.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$35.00K 10-Q · filed 2024-08-29 | -$183.00K 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |